Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for <i>ERBB2</i>-Positive Breast Cancer
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), Patrick Neven(KU Leuven), Päivi Halonen(University of Helsinki), Helena Granstam-Björneklett(Västerås Municipality), Päivi Auvinen(University of Eastern Finland), Minna Tanner(Tampere University Hospital), Riikka Huovinen(Turku University Hospital), Meri Utriainen(University of Helsinki), Judith Fraser(Beatson West of Scotland Cancer Centre), Liisa Sailas(Turku University Hospital), Teppo Huttunen, Hans Wildiers, Pirkko‐Liisa Kellokumpu‐Lehtinen, Vernon Harvey(Auckland City Hospital), Kenneth Villman(Örebro University Hospital), Jeffrey Yachnin(Karolinska University Hospital), Peter Canney(Beatson West of Scotland Cancer Centre), Taina Turpeenniemi‐Hujanen(Oulu University Hospital)
Cited by 2
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k